TABLE 4

Effects of the nine different drugs on the mRNA expression of different mitochondrial-related genes

The results, which are expressed as a fold-change of untreated nonsteatotic (NS) cells, are mean ± S.E.M. for four independent cultures. Statistical analysis was performed with two-way ANOVA: T, effect of treatment, S, effect of steatosis. Individual means were then compared with the post hoc Bonferroni test.

DrugMT-ND1MT-CO2COX4I1PGC1APGC1BNRF1TFAMPOLGPOLRMT
EffectExpressionEffectExpressionEffectExpressionEffectExpressionEffectExpressionEffectExpressionEffectExpressionEffectExpressionEffectExpression
Amiodarone
20 µMNST1.30 ± 0.06a1.34 ± 0.30T1.15 ± 0.16aT2.26 ± 0.41a,b,c0.74 ± 0.101.09 ± 0.211.00 ± 0.120.99 ± 0.120.95 ± 0.14
S1.22 ± 0.05a1.13 ± 0.151.41 ± 0.12a1.98 ± 0.14a,b,c0.63 ± 0.061.10 ± 0.021.11 ± 0.081.13 ± 0.041.01 ± 0.07
Atorvastatin
5 µMNST1.51 ± 0.25aT2.16 ± 0.43a,b,cT1.68 ± 0.31a1.06 ± 0.02T1.35 ± 0.10aT2.95 ± 0.88a,b,c1.52 ± 0.18T2.14 ± 0.56aT1.84 ± 0.40a
S1.41 ± 0.26a1.57 ± 0.40a1.71 ± 0.23a1.13 ± 0.041.25 ± 0.15a,b,c2.02 ± 0.45a1.45 ± 0.081.84 ± 0.27a1.55 ± 0.26a
Carbamazepine
300 µMNS1.02 ± 0.071.45 ± 0.340.94 ± 0.04T0.77 ± 0.12a0.84 ± 0.130.91 ± 0.110.85 ± 0.040.87 ± 0.09T0.86 ± 0.06a
S0.85 ± 0.151.41 ± 0.190.88 ± 0.150.63 ± 0.10a0.75 ± 0.211.11 ± 0.530.83 ± 0.200.87 ± 0.110.73 ± 0.12a
Imipramine
60 µMNST1.16 ± 0.04a0.96 ± 0.18T1.53 ± 0.11a,b,cT3.20 ± 0.22a,b,c1.03 ± 0.141.04 ± 0.111.06 ± 0.011.18 ± 0.081.12 ± 0.05
S1.22 ± 0.12a1.05 ± 0.191.85 ± 0.21a,b,c3.25 ± 0.33a,b,c0.89 ± 0.101.02 ± 0.101.08 ± 0.081.23 ± 0.141.00 ± 0.06
Lovastatin
5 µMNST1.23 ± 0.03a,b,cT1.32 ± 0.22aT1.27 ± 0.06a,b,cT1.36 ± 0.14aT, S1.37 ± 0.14a1.00 ± 0.14T1.26 ± 0.11aT1.37 ± 0.15aT1.33 ± 0.13a
S1.15 ± 0.03a1.68 ± 0.11a1.34 ± 0.05a,b,c1.38 ± 0.09a1.05 ± 0.08a0.97 ± 0.131.41 ± 0.08a1.29 ± 0.10a1.20 ± 0.08a
Perhexiline
30 µMNS0.92 ± 0.07T1.38 ± 0.06aT1.23 ± 0.04aT1.89 ± 0.19a,b,c0.93 ± 0.110.91 ± 0.050.92 ± 0.150.91 ± 0.09T0.81 ± 0.06a
S0.87 ± 0.191.36 ± 0.20a1.26 ± 0.12a1.78 ± 0.08a,b,c0.82 ± 0.110.92 ± 0.060.95 ± 0.050.91 ± 0.090.84 ± 0.05a
Ritonavir
45 µMNST1.93 ± 0.17a,b,cT1.36 ± 0.23aT, S1.82 ± 0.10a,b,cT3.47 ± 0.28a,b,cT, S1.48 ± 0.10aT1.84 ± 0.18a,b,cT1.72 ± 0.12aT1.46 ± 0.13aT1.40 ± 0.15a
S1.72 ± 0.14a,b,c1.76 ± 0.17a,b,c2.17 ± 0.08a,b,c,d2.81 ± 0.36a,b,c1.12 ± 0.23a1.85 ± 0.08a,b,c2.05 ± 0.36a,b,c1.73 ± 0.23a,b,c1.38 ± 0.18a
Terbinafine
100 µMNST0.73 ± 0.06a,b,c1.34 ± 0.290.95 ± 0.071.28 ± 0.15T0.56 ± 0.07a,b,c0.89 ± 0.17T0.74 ± 0.09a,b,cT0.75 ± 0.03aT0.63 ± 0.02a,b,c
S0.84 ± 0.09a1.48 ± 0.311.04 ± 0.141.00 ± 0.120.67 ± 0.12a1.25 ± 0.350.96 ± 0.04a0.97 ± 0.11a0.88 ± 0.09a
Troglitazone
50 µMNST1.38 ± 0.08aT2.07 ± 0.26a,b,c1.10 ± 0.011.13 ± 0.06T1.37 ± 0.17a1.00 ± 0.051.07 ± 0.061.00 ± 0.081.09 ± 0.06
S1.46 ± 0.24a,b,c2.18 ± 0.26a,b,c1.43 ± 0.241.19 ± 0.241.23 ± 0.19a0.93 ± 0.061.31 ± 0.171.39 ± 0.291.17 ± 0.08
  • a Data indicates statistically significant difference with two-way ANOVA.

  • b Data indicates statistically significant difference with the post hoc Bonferroni test.

  • c Significantly different from untreated NS or S cells.

  • d Significantly different from NS cells (P < 0.05).